CAS: 2856-63-5; 2-(2-Chlorophenyl)Acetonitrile

上下游产品

CAS号694-80-4 2-溴氯苯 | CAS号17729-59-8 Tributyl(cyanom... | CAS号10442-39-4 氰化四丁基胺 | CAS号1058649-12-9 2-chloro-1-(met... | CAS号13078-80-3 2-(2-氯苯基)乙胺 | CAS号143-33-9 氰化钠 | CAS号611-19-8 邻氯氯苄 | CAS号17849-38-6 2-氯苄醇 | CAS号55154-88-6 2-氯苯乙脒 | CAS号57486-68-7 2-氯苯乙酸甲酯 | CAS号143328-25-0 2-[(7-Methoxy-5... | CAS号143433-73-2 sodium,(6R,7R)-... | CAS号40061-54-9 邻氯苯乙酸乙酯 | CAS号191328-21-9 4-(2-氯苯基)-4-哌啶甲腈 | CAS号21742-26-7 (2-chlorophenyl... | CAS号89-98-5 邻氯苯甲醛 | CAS号28049-59-4 1-(2-氯苯基)环丁烷-1-腈 | CAS号2958-36-3 2-氨基-2',5-二氯二苯甲酮

邻氯苄醇置于五氯化磷体系中,用 二甲基亚砜 用作溶剂,化学反应生成邻氯苯乙腈
参考文献:Henrick,C.A. Et Al.,Australian Journal Of Chemistry,1970,Vol. 23,P. 329-339
标题:Henrick,C.A. Et Al.,Australian Journal Of Chemistry,1970,Vol. 23,P. 329-339

专利信息

专利号:US-4822903-A
优先权日:1981-05-15
标题:Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof
发明人：JACQUES ROLAND; REPPELIN MICHEL; SEIGNEURIN LAURENT
权利人:RHONE POULENC SPEC CHIM
摘要:An improved fluorinated siliceous catalyst, well adapted for the catalytic synthesis of aromatic/aliphatic nitriles from their corresponding formamides, formanilides or amides, is comprised of a plurality of silica particulates, the specific surface of which ranging from about 200 to about 300 m 2 /g, having a total pore volume ranging from about 1 to about 1.5 cm 3 /g, with an average pore diameter ranging from about 100 to about 200 â„«, having an exchange pH of less than about 3, and with the fluorine content thereof bonded to the silica, expressed in F 31 , ranging from about 0.05 to about 2% by weight based upon the silica, and the sodium content thereof, expressed as Na 2 O, being less than about 1% by weight, also based upon the silica.

专利号:US-4369322-A
优先权日:1978-12-15
标 题 :Process for the production of substituted acetonitriles
发明人：SCHALKE PETER; KLEEMANN AXEL
权利人:DEGUSSA
摘要:The known synthesis for the production of aromatic substituted acetonitriles by reaction of aromatic substances with cyanogen chloride in the gas phase is improved by feeding the starting materials in gaseous form and separated from each other into the reactor. The process can be used to synthesize in general aromatic and especially hetero-aromatic substituted acetonitrile.

专利号:US-7501407-B2
优先权日:2001-12-20
标题 :Pyrimidine A2B selective antagonist compounds, their synthesis and use
发明人：CASTELHANO ARLINDO; MCKIBBEN BRYAN; STEINIG ARNO; COLLINGTON ERIC
权利人:OSI PHARM INC
摘要:The subject invention provides compounds having the structure: n nwherein R 1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R 2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R 3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 2 and R 3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R 3 is oxygen; R 4 and R 5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 4 NR 5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms;n R 12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A 2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.

专利号:US-5922722-A
优先权日:1996-11-12
标 题 :Alpha 1a adrenergic receptor antagonists
发明人：BOCK MARK G; PATANE MICHAEL A; PONTICELLO ROSE ANN
权利人:MERCK & CO INC
摘要:PCT No. PCT/US96/18321 Sec. 371 Date Apr. 22, 1998 Sec. 102(e) Date Apr. 22, 1998 PCT Filed Nov. 12, 1996 PCT Pub. No. WO97/17967 PCT Pub. Date May 22, 1997This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These componds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

专利号:US-4460604-A
优先权日:1976-06-03
标 题 :4-Amino-4-aryl-cyclohexanones
发明人：LEDNICER DANIEL
权利人:UPJOHN CO
摘要:A class of 4-amine-4-arylcyclohexanones, their ketals, and acid addition salts have been synthesized and found to be useful for relieving pain in animals. Their analgesic activity appears to be of high order, and in addition some exhibit narcotic antagonist activity that is useful in modifying the cardiovascular, respiratory, and behavioral depression caused by other analgesics. Several show mixed analgesic and narcotic antagonist activity. Preferred compounds of the class are 4-(m-hydroxyphenyl)-4-dimethylaminocyclohexanone ethylene ketal, and 4-(m-hydroxyphenyl)-4-(n-butylmethylamino)cyclohexanone ethylene ketal as free bases and as their hydrochloride salts. Processes for synthesis and intermediates are described. Unit dosage forms and therapeutic treatments are disclosed.

专利号:US-6274583-B1
优先权日:1995-06-07
标题:Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; BOCK MARK G; NEWTON RANDALL C
权利人:MERCK & CO INC
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.